Colorectal cancer liver metastases (CRLM) are common and found in almost 50% of patients with colorectal cancer. Surgical resection has proved to be the most effective therapy for metastatic colorectal cancer isolated to the liver and has yielded long term survival. However, recurrence frequently occurs within the remaining liver as well as at extra-hepatic sites. The role of adjuvant therapy has been investigated in many studies but has still been controversial until now. This review examines the incorporation of adjuvant systemic chemotherapy, regional chemotherapy with hepatic arterial infusion and molecular targeted therapy following liver resection for patients with CRLM, and summarized the advantage and adverse effects for these treatments. Finally, we propose the prospective of future adjuvant treatments to further improve prognosis.
In China, Colla corii asini is a health-care food and traditional Chinese medicine widely used in life-nourishing and clinical hematic antanemic therapy for more than 2,000 years. In this paper we compiled the chemical constituents isolated and detected from Colla corii asini including amino acids, proteins/gelatins, polysaccharides, volatile substances, inorganic substances, etc. Meanwhile we investigated the biological activities of Colla corii asini, which have been reported over the past few decades, including, hematologic diseases inhibitory activities, anti-aging activity, antitumor activity, immunomodulatory activity, bone repair activity, anti-inflammatory activity, antifatigue activity, etc. However, few reports on the relationships between the chemical constituents and bioactivities have been found, further studies of Colla corii asini are still necessary to facilitate research and development in the future.
Isotryptoquivaline F (1) was isolated from Aspergillus sp. CM9a, an endophytic fungus of Cephalotaxus mannii. The structure was elucidated by extensively 1D and 2D NMR and HR ESI MS spectroscopy. It has good TNF-α antagonistic effect, and can be used for anti-inflammatory drugs or other bioactive leading drugs.
In eukaryotes, the Mediator complex is an essential transcriptional cofactor of RNA polymerase II (Pol II). In humans, it contains up to 30 subunits and consists of four modules: head, middle, tail, and CDK/Cyclin. One of the subunits, MED15, is located in the tail module, and was initially identified as Gal11 in budding yeast, where it plays an essential role in the transcriptional regulation of galactose metabolism with the potent transcriptional activator Gal4. For this reason, we investigated the function of the human MED15 subunit (hMED15) in transcriptional activation. First, we measured the effect of hMED15 knockdown on cell growth in HeLa cells. The growth rate was greatly reduced. By immunostaining, we observed the colocalization of hMED15 with the general transcription factors TFIIE and TFIIH in the nucleus. We measured the effects of siRNA-mediated knockdown of hMED15 on transcriptional activation using two different transcriptional activators, VP16 and SREBP1a. Treatment with siRNAs reduced transcriptional activation, and this reduction could be rescued by overexpression of HA/Flag-tagged, wild-type hMED15. To investigate hMED15 localization, we treated human MCF-7 cells with the MDM2 inhibitor Nutlin-3, thus inducing p21 transcription. We found that hMED15 localized to both the p53 binding site and the p21 promoter region, along with TFIIE and TFIIH. These results indicate that hMED15 promotes transcriptional activation.
Eriodictyol is a flavanone well-known for its antioxidative activity. Due to a chiral carbon atom in position C-2, eriodictyol always exist in racemic form. In order to study the a Chiral Amylose-C column as chiral stationary phase. Online coupling HPLC-circular dichroism (CD) method was used for the determination of elution order and the absolute configurations of the two eluates. The protective effects of racemic and enantiomeric eriodictyol against H2O2-induced cytotoxicity with EA.hy926 cells were tested. The results showed that the two enantiomers of eriodictyol and the corresponding racemate were equipotent, suggesting that the configuration of the C-2 chiral center does not influence the cytoprotective activity against H2O2-induced oxidative stress in EA.hy926 cells.
Histone deacetylases (HDACs) have attracted a great deal of interest as anticancer drug targets, and many HDAC inhibitors (HDACIs) have displayed clinical efficacy in treating specific tumors. However, all of these agents have significant toxicity, including fatigue, nausea, vomiting, thrombocytopenia, and neutropenia. Thus, increased effort is being directed toward developing selective HDACIs that are tolerated better and cause fewer adverse reactions. This article focuses mainly on the N-hydroxycinnamamide-based HDAC 1/3 dual inhibitors, and this article outlines the anticancer potential of these inhibitors. Since selective HDAC1/3 inhibitors may cause fewer adverse reactions than selective pan-HDACIs and selective Class Ι inhibitors in clinical settings, further study of their mechanism of anticancer activity and optimization of their structure is warranted.
The Ebola outbreak in West Africa this year is causing global panic. The high mortality of this disease is largely due to lack of effective preventive vaccines or therapeutic drugs. Realizing the gravity and urgency in controlling the epidemic, governments and drug companies across the world have taken many strong measures to speed up the process of drug development. Several representative candidate drugs that demonstrate potent anti-Ebola activity in preclinical studies have been pushed forward to higher research stages to obtain an earlier official license. It is expected that proven preventive or therapeutic regimens could be established in the near future.
August 28, 2017 There had been a service stop from Aug 28‚ 2017‚ 1:50 to Aug 28‚ 2017‚ 10:08(JST) (Aug 27‚ 2017‚ 16:50 to Aug 28‚ 2017‚ 1:08(UTC)) . The service has been back to normal.We apologize for any inconvenience this may cause you.
July 31, 2017 Due to the end of the Yahoo!JAPAN OpenID service, My J-STAGE will end the support of the following sign-in services with OpenID on August 26, 2017: -Sign-in with Yahoo!JAPAN ID -Sign-in with livedoor ID * After that, please sign-in with My J-STAGE ID.
July 03, 2017 There had been a service stop from Jul 2‚ 2017‚ 8:06 to Jul 2‚ 2017‚ 19:12(JST) (Jul 1‚ 2017‚ 23:06 to Jul 2‚ 2017‚ 10:12(UTC)) . The service has been back to normal.We apologize for any inconvenience this may cause you.
May 18, 2016 We have released “J-STAGE BETA site”.
May 01, 2015 Please note the "spoofing mail" that pretends to be J-STAGE.
Edited and published by : International Research and Cooperation Association for Bio & Socio-Sciences Advancement Produced and listed by : International Advancement Center for Medicine & Health Research